Rua Bioscience (RUA)•HY26•Released 27 February 2026Revenue grew to NZ$1.3m but losses persisted as borrowings quadrupledA 4.5x step-up in debt funded most of the cash uplift while total assets sit below the supplied historical range.Published 22 May 2026Read briefing→
Rua Bioscience (RUA)•FY25•Released 1 September 2025RUA revenue rose 490.6% but the business remains deeply cash-negativeStrong commercial momentum cut the loss before tax by 74.8%, yet cash fell to NZD 0.2m and operating outflows persist, making runway the centralPublished 19 May 2026Read briefing→
Rua Bioscience (RUA)•HY24•Released 29 February 2024Goodwill impairment of $8.3m drives HY24 loss of $10.9mManagement writes off a prior acquisition that failed to deliver, leaving a $1.0m cash buffer and ongoing operating burn.Published 28 April 2026Read briefing→
Rua Bioscience (RUA)•FY23•Released 29 August 2023Customer revenue $0.4m as cash burn $5.9m leaves $2.5m on handHeadline revenue of $6.5m is dominated by fair value gains on contingent consideration; commercial revenue remains immaterial against ongoing burn.Published 23 April 2026Read briefing→
Rua Bioscience (RUA)•HY23•Released 28 February 2023Reported $0.7m profit masks unchanged $3.7m cash burn against $1.7m balanceNon-cash items drove the swing to NPAT while operating cash outflow held near prior levels and the cash balance fell 24.5%.Published 23 April 2026Read briefing→
Rua Bioscience (RUA)•FY22•Released 29 August 2022Cash falls to $1.9m as operating burn widens to $6.8mFirst product sales arrived but losses widened materially, leaving only months of cash at the current operating burn rate.Published 22 April 2026Read briefing→
Rua Bioscience (RUA)•HY22•Released 25 February 2022Operating cash burn nearly doubled to $3.7m before first revenueHeadline cash fell from $19.2m to $2.3m as Rua moves to commercialisation, with the loss widening only modestly.Published 22 April 2026Read briefing→